Guernsey approves Cladribine
24/07/2019
Guernsey has just approved the use of Cladribine (Mavenclad) for people with highly active MS. Cladribine works by killing certain types of cells made by your immune system. These cells would normally attack viruses and bacteria that enter the body. However, in MS these cells attack the myelin around the nerves in the brain or spinal cord.
Cladribine therefore has the result of reducing the number of these immune cells available which are damaging the myelin sheath, and so helps to reduce the amount of damage to the brain and spinal cord.
For further information on Cladribine please click the link below: